Gen Era and EDH have joined forces - EDH Nükleer Tıp & Sağlık Hizmetleri

Gen Era Diagnostics and EDH Nuclear Medicine and Healthcare Services have joined forces by bringing together their expertise in personalized diagnosis and treatment.

Gen Era, a leading genomics services company for Next Generation Sequencing (NGS), Molecular Biology, Bioinformatics and Life Sciences, moving on to shape the future of these projects from today, with technical knowledge and protocols covering a wide range of applications, as one of the first service providers in Turkey in the field of NGS. Expanding the geographies, it serves by offering to its stakeholders short turnaround times, competitive pricing and unmatched scientific support, Gen Era reinforces its pioneering role in the development of innovative products with RefGen, which it has recently acquired.

EDH, the authorized representative of the world’s leading companies in the nuclear medicine industry in more than 20 countries; operates in Turkey, Europe and the Middle East with its personalized cancer diagnosis and treatment products. In addition to its sales, distribution and technical service activities of radiopharmaceutical production, quality control and imaging equipment, EDH offers leading products used in targeted therapy to the use of researchers thanks to its business partners in the USA and continues to develop new products with its business partners in Europe.

With the synergy brought by the merger, Gen Era will strengthen its position in the global market with bioinformatics software, Next Generation Sequencing solutions and niche products in personalized oncology to complete the value chain in the fields of molecular/genetic diagnosis and targeted therapy, which are becoming increasingly important in today’s world. The goal is to be more active in markets outside Turkey with a fast and strong geographical growth strategy, including potential inorganic growth in the near future. After the restructuring, activities in the field of nuclear medicine and radiotheranostics will continue under the existing EDH brand.

Gen Era Managing Partners Alper Emrah İşeri and Murat Topaloğlu commented regarding the merger:

“While we increase our knowledge in niche areas thanks to the complementary products and services of EDH and Gen Era, we believe that this merger will add great strength and value to us in our journey to open up to global markets. In addition to the products offered to the market by EDH, especially in the field of personalized oncology, we are excited to be able to offer innovative products to all our stakeholders with a holistic approach and the use of our diagnostic solutions that we are developing within Refgen. In addition, we think that the visionary approach of both companies, good relations with their stakeholders and having core values such as business ethics will be very important for the success of the new structure.”

EDH Founder and General Manager Hasan Ulaş Özcan also commented:

“We are very happy to be a part of the Gen Era family, which has gained a well-deserved appreciation in the national and international arena for its extraordinary development and achievements in the fields of genetics and life sciences. We are excited to start our journey with the aim of being among the important players of the future healthcare within Gen Era thanks to our team especially experienced in the nuclear medicine, medical device and clinical research sectors who has developed long-term relationships with global players.”